Every few years, a class of medications arrives that genuinely changes the conversation. GLP-1 receptor agonists — semaglutide, tirzepatide, liraglutide — are that class. They are being prescribed in record numbers, covered on front pages, and discussed in boardrooms and living rooms alike. And yet most people, including many patients actively taking them, have only a partial picture of what these drugs actually do, why they work, who truly benefits, and — critically — what they leave untouched.
This article is an attempt to give you that fuller picture. No hype. No fear. Just the science, the data, and an honest assessment of where GLP-1 therapy fits inside a serious longevity medicine practice.
First: What Is GLP-1?
GLP-1 stands for glucagon-like peptide-1. It is not a pharmaceutical invention. It is a hormone your body produces naturally — released from specialised cells in your small intestine, called L-cells, within minutes of eating.
Its job is elegant and multifaceted. When food arrives in your gut, GLP-1 signals the pancreas to release insulin in a glucose-dependent manner — meaning it only drives insulin secretion when blood glucose is actually elevated. This is a crucial safety feature that distinguishes it from older diabetes drugs. Simultaneously, GLP-1 suppresses glucagon (the hormone that raises blood sugar), slows gastric emptying so nutrients enter the bloodstream more gradually, and travels to the brain — specifically the hypothalamus and brainstem — where it reduces appetite and increases the sense of satiety.
In a healthy metabolic state, this system hums along beautifully. After a meal, GLP-1 rises, appetite is suppressed, insulin does its job, and within a few hours, levels return to baseline. The problem is that in individuals with obesity, insulin resistance, or type 2 diabetes, this system becomes blunted. Post-meal GLP-1 responses are attenuated. The satiety signal is quieter. The metabolic orchestra is playing, but some instruments have gone slightly out of tune.
The key insight: GLP-1 receptor agonists do not introduce a foreign mechanism into your body. They amplify and extend a signal your body already uses — they just make it louder, longer-lasting, and more reliable than your own endogenous hormone can achieve.
How GLP-1 Receptor Agonists Actually Work
GLP-1 receptor agonists are synthetic molecules designed to bind to the same GLP-1 receptor that your natural hormone targets — but with key differences. Native GLP-1 has a half-life of less than two minutes before enzymes called DPP-4 break it down. Pharmaceutical GLP-1 RAs are engineered to resist this degradation, giving them half-lives ranging from hours (liraglutide) to approximately one week (semaglutide).
This sustained receptor activation produces a cascade of effects across multiple organ systems:
- Pancreas: Glucose-dependent insulin secretion is enhanced; glucagon is suppressed, reducing hepatic glucose output.
- Stomach: Gastric emptying is slowed, blunting post-meal blood sugar spikes and extending fullness.
- Brain: Appetite-regulating centres in the hypothalamus receive a prolonged satiety signal, reducing hunger and food-seeking behaviour — not through willpower, but through neurochemistry.
- Liver: Emerging evidence suggests direct effects on hepatic lipid metabolism, reducing fatty liver accumulation.
- Heart and vasculature: Direct anti-inflammatory and anti-atherosclerotic effects, independent of weight loss, are increasingly supported by trial data.
The dual agonist tirzepatide adds activation of the GIP (glucose-dependent insulinotropic polypeptide) receptor, which appears to amplify weight loss and glycaemic benefits further — a significant step forward from single-receptor GLP-1 agonists.
What the Clinical Evidence Actually Shows
We now have robust trial data — not anecdote, not influencer testimonial, but large, randomised, controlled trials with hard outcomes. Here is what the evidence says.
Weight Loss: The SURMOUNT Trials
The SURMOUNT programme, studying tirzepatide in adults with obesity (without diabetes), produced results that genuinely surprised the research community. In SURMOUNT-1, published in the New England Journal of Medicine in 2022, participants receiving the highest dose (15 mg weekly) achieved a mean weight reduction of 22.5% of body weight over 72 weeks. Approximately 57% of participants lost 20% or more of their body weight.
To put that in context: prior to GLP-1 RAs, pharmacological weight loss rarely exceeded 5–10%. Bariatric surgery typically achieves 25–30%. Tirzepatide is approaching surgical outcomes in a significant proportion of patients — without an operating theatre.
Semaglutide's STEP trials showed comparable, if slightly lower, results — approximately 15% mean body weight reduction at the highest dose (2.4 mg weekly subcutaneous), with meaningful improvements in cardiometabolic markers across the board.
Cardiovascular Outcomes: The SELECT Trial
Weight loss is meaningful. But what longevity medicine ultimately cares about is whether interventions reduce the risk of dying from — or being disabled by — the diseases that cut lives short. This is where the SELECT trial changes the calculus.
SELECT, published in the New England Journal of Medicine in late 2023, enrolled over 17,600 adults with established cardiovascular disease and overweight or obesity (but without diabetes). Participants were randomised to semaglutide 2.4 mg weekly or placebo, on top of standard care, for up to five years.
The result: semaglutide reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 20% relative to placebo. This is a substantial, clinically meaningful reduction in hard cardiovascular events — in people who were not diabetic — suggesting that GLP-1 RAs have cardiovascular benefits that extend beyond glycaemic control and even beyond weight loss itself.
Analyses from SELECT suggest that only a portion of the cardiovascular benefit can be explained by weight loss alone. The anti-inflammatory, endothelial-stabilising, and direct cardiac effects of GLP-1 receptor activation appear to contribute independently — a finding with significant implications for how we think about these drugs in longevity medicine.
Earlier trials in type 2 diabetes — LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) — had already established cardiovascular benefit in diabetic populations. SELECT extends this benefit to a far broader group.
Who Is an Appropriate Candidate?
The evidence base is strongest, and the benefit-risk calculation most clearly favourable, in specific clinical profiles. A thoughtful assessment matters here — these are not benign supplements, and candidacy should be determined by a clinician who understands your full metabolic picture.
Strong evidence supports GLP-1 RA use in:
- Adults with type 2 diabetes and established or high-risk cardiovascular disease
- Adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity — hypertension, dyslipidaemia, obstructive sleep apnoea, non-alcoholic fatty liver disease, or pre-diabetes
- Adults with established atherosclerotic cardiovascular disease and excess adiposity, regardless of diabetes status (SELECT population)
- Adults with metabolic syndrome whose risk trajectory is heading toward irreversible organ damage
The picture is more nuanced — and the evidence thinner — for individuals who are metabolically healthy but wish to lose modest amounts of weight for aesthetic reasons, or for those in whom the underlying drivers of weight gain have not been properly investigated.
There are also clear contraindications: personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, active pancreatitis, and certain gastrointestinal conditions. Pregnancy requires careful discussion. Side effects — predominantly nausea, vomiting, constipation, and transient fatigue — are common in the early titration phase and, for most patients, manageable. Rare but serious adverse events require appropriate monitoring.
What GLP-1 Agonists Do Not Fix
This is the part of the conversation that tends to get lost in the excitement — and it is, frankly, the part I feel most compelled to emphasise.
GLP-1 receptor agonists are powerful tools. They can shift the trajectory of metabolic disease in ways we could not achieve a decade ago. But they work downstream of the causes — they treat the phenotype of metabolic dysfunction, not its origins.
They do not fix:
- Chronic sleep deprivation — which drives cortisol dysregulation, impairs leptin and ghrelin signalling, and promotes visceral fat accumulation independent of caloric intake
- Chronic psychological stress — which sustains HPA axis activation, promotes inflammatory cytokine production, and creates the neurochemical substrate for dysregulated eating
- Nutritional insufficiency — reduced appetite on GLP-1 therapy means reduced food intake, which means micronutrient deficits become a genuine clinical concern if dietary quality is not addressed
- Muscle mass loss — weight loss from GLP-1 RAs includes a significant lean mass component; without deliberate resistance training and adequate protein intake, patients can lose metabolically precious muscle alongside fat
- Gut dysbiosis or intestinal permeability — emerging as significant contributors to metabolic inflammation; GLP-1 RAs do not restore a disordered microbiome
- Hormonal imbalances — thyroid dysfunction, sex hormone deficiencies, and adrenal dysregulation can all contribute to weight gain and metabolic risk; GLP-1 therapy does not address these
- Environmental toxin burden — endocrine-disrupting chemicals stored in adipose tissue are released during rapid fat loss; supporting detoxification pathways during this process matters
And perhaps most importantly: GLP-1 RAs are typically a long-term, possibly indefinite, intervention. The STEP-4 trial demonstrated clearly that weight regains substantially — an average of two-thirds of lost weight within one year — when semaglutide is discontinued without accompanying lifestyle change. The drug manages the condition; it does not cure it. For many patients, this is entirely acceptable and appropriate. But it must be an informed decision, not a surprise discovery.
"A medication that silences your appetite does not teach you why you were hungry in the first place. And in medicine, the questions we stop asking are often the ones that matter most. GLP-1 therapy, at its best, buys us time and metabolic space — but that space must be filled with something. With understanding. With restored function. With a body that is not just lighter, but genuinely healthier at its foundation."
— Dr. Sadaf Mubeen Mirza, CLP, AFMCP
The Longyx Approach to GLP-1 Therapy
At Longyx, we do not reflexively prescribe, and we do not reflexively withhold. What we do is assess.
Before any GLP-1 discussion, we want to understand the full metabolic landscape. That means looking at fasting insulin and HOMA-IR, not just blood glucose. It means evaluating thyroid function comprehensively — TSH, free T3, free T4, thyroid antibodies — because undiagnosed hypothyroidism is a common, correctable driver of weight gain and fatigue. It means reviewing cortisol rhythm, sex hormone status, inflammatory markers including high-sensitivity CRP, and detailed lipid fractionation including ApoB and Lp(a).
It means asking about sleep architecture, stress biology, movement patterns, and nutritional quality — not as a box-ticking exercise, but because these are the inputs that determine whether a person on GLP-1 therapy builds lasting metabolic resilience or simply loses weight while the underlying system remains fragile.
If GLP-1 therapy is appropriate — and in many patients, it genuinely is — we integrate it into a broader protocol. That protocol includes:
- Nutritional guidance that accounts for reduced appetite and prioritises protein density and micronutrient sufficiency
- A resistance training framework designed to protect lean mass during weight loss
- Monitoring of body composition, not just scale weight — because a number on a scale tells us nothing about the ratio of muscle to fat being lost
- Ongoing assessment of the metabolic drivers that preceded the weight gain, with targeted interventions for each
- A clear, honest conversation about what happens when and if the medication is eventually deprescribed
GLP-1 therapy at its most effective is not a prescription handed across a desk. It is a carefully contextualised intervention inside a relationship between a clinician and a patient who both understand the goal: not a lower number on a scale, but a longer, more functional, more vital life.
A note on the broader evidence horizon: Research into GLP-1 RAs is moving rapidly. Trials are underway examining their role in heart failure with preserved ejection fraction (STEP-HFpEF has already shown benefit), non-alcoholic steatohepatitis, chronic kidney disease, Alzheimer's disease risk, and addiction medicine. The biology of GLP-1 receptors — expressed in the brain, heart, kidneys, gut, and immune cells — suggests we are likely only beginning to understand the full therapeutic reach of this hormone system.
The Bottom Line
GLP-1 receptor agonists represent a genuine advance in the treatment of obesity and metabolic disease. The SURMOUNT and SELECT trial data are not marketing claims — they are robust, peer-reviewed, landmark findings that have legitimately shifted clinical practice guidelines worldwide.
But a powerful tool is not the same as a complete solution. The patients who do best on these medications are those who use the metabolic improvement they provide as a foundation — not a finish line. Those who also address sleep, stress, movement, nutrition, and the specific hormonal and inflammatory drivers that put them at risk in the first place.
If you are curious about whether GLP-1 therapy is appropriate for you, the starting point is not a prescription — it is a conversation grounded in your full clinical picture. That is what we offer at Longyx. Not a fast answer, but the right one.